Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.57 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.57 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18581467 | 0.83 | ADRB1 (0.49) | ADRB1ADRB3ENPP3ENPP1 | |
| SCHEMBL6326255 | 0.81 | ADRB1 (0.53) | ADRB1ADRB3ENPP3ENPP1LTA4H | |
| SCHEMBL2707290 | 0.80 | ENPP3 (0.53) | ADRB1ADRB3ENPP3ENPP1MEN1 | |
| SCHEMBL201354 | 0.80 | DHODH (0.51) | ADRB1ADRB3ENPP3ENPP1LTA4H | |
| SCHEMBL6327924 | 0.78 | ADRB1 (0.52) | ADRB1ADRB3ENPP3ENPP1LTA4H | |
| SCHEMBL6326703 | 0.78 | ADRB1 (0.51) | ADRB1ADRB3ENPP3ENPP1TAAR1 | |
| SCHEMBL6326200 | 0.72 | ENPP3 (0.60) | ADRB1ADRB3ENPP3ENPP1LTA4H | |
| SCHEMBL9520916 | 0.71 | ENPP3 (0.46) | ADRB1ADRB3ENPP3ENPP1LTA4H | |
| SCHEMBL11579595 | 0.71 | LTA4H (0.72) | LTA4HTAAR1PLA2G2ARAB9ASMN1; SMN2 | |
| SCHEMBL6492917 | 0.71 | ADRB1 (0.39) | ADRB1ADRB3ENPP3ENPP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | claimed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | claimed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | claimed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | claimed |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-6706743-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2004-03-16 | — | — | US | disclosed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | ADRB1 2/4885ADRB3 1/4885ENPP3 1633/4885 |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | ADRB1 2/4885ADRB3 1/4885ENPP3 1438/4885 |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | ADRB1 3/4885ADRB3 1/4885ENPP3 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.